Breaking News

Breaking news filtered in real-time to show only the most impactful headlines for US-listed public companies.

IMMUNOVANT INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT

(NASDAQ:IMVT) NEW YORK and NEW ORLEANS, Aug. 29, 2025 /PRNewswire/ -- The law firm of Kahn Swick & Foti, LLC ("KSF") has commenced an investigation into Immunovant, Inc. (NasdaqGS: IMVT) ("Immunova...

How will the market perception of Immunovant’s fiduciary compliance risk influence short‑term liquidity and trading volume for IMVT? Could the investigation lead to changes in the company's leadership or governance structure, and what impact might that have on operational continuity? What potential financial penalties or legal liabilities could arise from the investigation and how might they affect Immunovant's balance sheet?
Symbol: IMVT
Lawsuits
19 days ago
Read more prnewswire

Northland Announces Reset Dividend Rate on Its Cumulative Rate Reset Preferred Shares, Series 1 & Series 2

(NPI) TORONTO, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Northland Power Inc. ("Northland" or the "Company") (TSX: NPI) today announced that pursuant to the share terms in respect of the Cumulative Rate ...

What are the potential implications of this dividend reset for Northland's capital structure, liquidity, and future growth prospects through 2030? What is the relative attractiveness of Northland's reset dividend compared to peer utilities and other preferred‑share issuers in the Canadian market? How will the 5.70% fixed dividend rate on Series 1 preferred shares influence Northland's common equity valuation and immediate price movement?
Symbol: NPI
Dividends
19 days ago
Read more globenewswire

Investor Alert: Robbins LLP Informs Investors that a Class Action Lawsuit Has Been Filed Against Semler Scientific, Inc.

(NASDAQ:SMLR) SAN DIEGO, Aug. 29, 2025 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of persons and entities that purchased or otherwise acquired Semler S...

What is the market's immediate reaction and liquidity impact on SMLR, and how should I adjust my position sizing or hedging strategy? How likely is the class action lawsuit to result in a material adverse event, such as a delisting or significant dilution, and what is the expected timeline? What is the estimated financial exposure and potential settlement amount for Semler Scientific, and how might that affect its valuation?
Symbol: SMLR
Lawsuits
19 days ago
Read more prnewswire

PicoCELA Inc. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

(NASDAQ:PCLA) TOKYO, Aug. 30, 2025 /PRNewswire/ -- PicoCELA Inc. ("PicoCELA" or the "Company") (Nasdaq: PCLA), a Tokyo-based provider of enterprise wireless mesh solutions, today announced that the...

What contingency plans does the company have if it fails to meet the required bid price and faces delisting? How might the notification affect liquidity and short‑term price volatility of PCLA shares? What is the potential timeline for PicoCELA to regain compliance with Nasdaq's minimum bid price requirement?
Symbol: PCLA
Regulation
19 days ago
Read more prnewswire

PicoCELA Inc. Issues Restricted Common Shares to MCC and You Planning

(NASDAQ:PCLA) TOKYO, Aug. 30, 2025 /PRNewswire/ -- On July 28, 2025, PicoCELA Inc. ("PicoCELA" or the "Company,") (NASDAQ: PCLA), a Tokyo-based provider of enterprise wireless mesh solutions, enter...

How does this capital raise compare to PicoCELA's recent financing activities and to similar financing moves by competitors in the enterprise wireless mesh market? What are the terms and conditions of the Share Subscription Agreements, including any lock‑up periods or voting rights, and how might they influence liquidity and control dynamics? How will the issuance of restricted common shares to MCC affect the company's diluted earnings per share and overall valuation?
Symbol: PCLA
Equity
19 days ago
Read more prnewswire

FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease

(NASDAQ:BIIB) LEQEMBI IQLIK is the first and only anti-amyloid treatment to offer an at-home injection to help patients and care partners continue to treat this progressive, relentless disease afte...

How might this at‑home delivery option influence market share dynamics against competitors like Eli Lilly's donanemab and other upcoming Alzheimer's treatments? What pricing strategy and reimbursement landscape can be expected for the subcutaneous injection compared to existing intravenous anti‑amyloid therapies? How will the FDA approval of LEQEMBI® IQLIK™ affect Biogen's projected revenue and earnings forecasts?
Symbol: BIIB
Regulatory
19 days ago
Read more prnewswire